Get started
Author

Debora Schmitz

Observed name: D. Schmitz
OpenAlex ID: A5032769129
NDR kinases regulate essential cell processes from yeast to humans
2006 · Alexander Hergovich, Mario R. Stegert, et al. · Nature Reviews Molecular Cell Biology · 323
The human tumour suppressor LATS1 is activated by human MOB1 at the membrane
2006 · Alexander Hergovich, Debora Schmitz, et al. · Biochemical and Biophysical Research Communications · 186
NDR Kinase Is Activated by RASSF1A/MST1 in Response to Fas Receptor Stimulation and Promotes Apoptosis
2008 · Anton Vichalkovski, Ekaterina Gresko, et al. · Current Biology · 161
PDF
The MST1 and hMOB1 Tumor Suppressors Control Human Centrosome Duplication by Regulating NDR Kinase Phosphorylation
2009 · Alexander Hergovich, Reto S. Kohler, et al. · Current Biology · 109
PDF
Differential NDR/LATS Interactions with the Human MOB Family Reveal a Negative Role for Human MOB2 in the Regulation of Human NDR Kinases
2010 · Reto S. Kohler, Debora Schmitz, et al. · Molecular and Cellular Biology · 74
Ablation of the Kinase NDR1 Predisposes Mice to the Development of T Cell Lymphoma
2010 · Hauke Cornils, Mario R. Stegert, et al. · Science Signaling · 72
Identification of CLEC12B, an Inhibitory Receptor on Myeloid Cells
2007 · Sabrina C. Hoffmann, Carola Schellack, et al. · Journal of Biological Chemistry · 52
PDF
Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer
2022 · Faye M Johnson, Filip Janku, et al. · The Oncologist · 21
Generation of Stable Human Cell Lines with Tetracycline-inducible (Tet-on) shRNA or cDNA Expression
2013 · Marta Gomez-Martinez, Debora Schmitz, et al. · Journal of Visualized Experiments · 15
Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutation
2019 · Filip Janku, Faye M. Johnson, et al. · Molecular Cancer Therapeutics · 7
Single-arm study of bimiralisib in head and neck squamous cell carcinoma (HNSCC) patients (pts) harboring NOTCH1 loss of function (LOF) mutations.
2020 · Faye M. Johnson, Filip Janku, et al. · Journal of Clinical Oncology · 6
A Dose-Escalation (DE) Study with Expansion Evaluating Safety, Pharmacokinetics and Efficacy of the Novel, Balanced PI3K/mTOR Inhibitor PQR309 in Patients with Relapsed or Refractory Lymphoma
2016 · Graham P. Collins, Rakesh Popat, et al. · Blood · 5
Generation of Stable Human Cell Lines with Tetracycline-inducible (Tet-on) shRNA or cDNA Expression
2013 · Marta Gomez-Martinez, Debora Schmitz, et al. · Journal of Visualized Experiments · 5
Cancer Biology and the Principles of Targeted Cancer Drug Discovery
2016 · P. Hillmann, D. Schmitz, et al. · Elsevier eBooks · 4
A phase 1 study of the PI3K/mTOR inhibitor PQR309 evaluating safety, pharmacokinetics (PK) and pharmacodynamics (PD) in patients (pts) with advanced solid tumors.
2016 · Alex A. Adjei, Grace K. Dy, et al. · Journal of Clinical Oncology · 4
Population pharmacokinetics of PQR309, a dual PI3K/mTOR inhibitor in adult patients with advanced solid tumors.
2016 · Matthias Machacek, Lionel Renaud, et al. · Journal of Clinical Oncology · 3
Abstract 378: Exploring intermittent dosing schedules for the Pan PI3K/mTor inhibitor PQR309
2016 · Karin Jorga, Debora Schmitz, et al. · Cancer Research · 2
Abstract 382: Concomitant administration of acid reducing agents can impact the pharmacokinetics of the balanced pan-PI3K and mTOR inhibitor PQR309
2016 · Karin Jorga, Eva Huehn, et al. · Cancer Research
Works count: 18
Citation count: 1,049
H-index: 9
I10-index: 9
Year
Topic
Type